A scientific journey from discovery to validation of efficacy in cancer patients: HAMLET and alpha1-oleate

James C.S. Ho; Ines Ambite; K. H. Mok; Marek Babjuk; Catharina Svanborg

doi:10.1080/23723556.2021.1974278

A scientific journey from discovery to validation of efficacy in cancer patients: HAMLET and alpha1-oleate

James C.S. Ho, Ines Ambite, K. H. Mok, Marek Babjuk, Catharina Svanborg

Research output: Contribution to journal › Article › peer-review

Abstract

The protein-lipid complex alpha1-oleate, derived from HAMLET (Human Alpha-lactalbumin Made LEthal to Tumor cells), is identified as a molecular entity with significant therapeutic potential. Structural characterization of the complex and results of a successful placebo-controlled clinical trial are presented.

Original language	English
Journal	Molecular and Cellular Oncology
Volume	8
Issue number	5
Early online date	2021
DOIs	https://doi.org/10.1080/23723556.2021.1974278
Publication status	Published - 2021

Subject classification (UKÄ)

Microbiology in the medical area

Free keywords

bladder cancer
low toxicity
Novel cancer therapy
peptide-oleate complex
protein folding

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/23723556.2021.1974278

Cite this

@article{d9096ae97a2d401196feb07cc1882c94,

title = "A scientific journey from discovery to validation of efficacy in cancer patients: HAMLET and alpha1-oleate",

abstract = "The protein-lipid complex alpha1-oleate, derived from HAMLET (Human Alpha-lactalbumin Made LEthal to Tumor cells), is identified as a molecular entity with significant therapeutic potential. Structural characterization of the complex and results of a successful placebo-controlled clinical trial are presented.",

keywords = "bladder cancer, low toxicity, Novel cancer therapy, peptide-oleate complex, protein folding",

author = "Ho, {James C.S.} and Ines Ambite and Mok, {K. H.} and Marek Babjuk and Catharina Svanborg",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.",

year = "2021",

doi = "10.1080/23723556.2021.1974278",

language = "English",

volume = "8",

journal = "Molecular and Cellular Oncology",

issn = "2372-3556",

publisher = "Taylor & Francis",

number = "5",

}

TY - JOUR

T1 - A scientific journey from discovery to validation of efficacy in cancer patients

T2 - HAMLET and alpha1-oleate

AU - Ho, James C.S.

AU - Ambite, Ines

AU - Mok, K. H.

AU - Babjuk, Marek

AU - Svanborg, Catharina

PY - 2021

Y1 - 2021

N2 - The protein-lipid complex alpha1-oleate, derived from HAMLET (Human Alpha-lactalbumin Made LEthal to Tumor cells), is identified as a molecular entity with significant therapeutic potential. Structural characterization of the complex and results of a successful placebo-controlled clinical trial are presented.

AB - The protein-lipid complex alpha1-oleate, derived from HAMLET (Human Alpha-lactalbumin Made LEthal to Tumor cells), is identified as a molecular entity with significant therapeutic potential. Structural characterization of the complex and results of a successful placebo-controlled clinical trial are presented.

KW - bladder cancer

KW - low toxicity

KW - Novel cancer therapy

KW - peptide-oleate complex

KW - protein folding

U2 - 10.1080/23723556.2021.1974278

DO - 10.1080/23723556.2021.1974278

M3 - Article

C2 - 34859140

AN - SCOPUS:85116386998

SN - 2372-3556

VL - 8

JO - Molecular and Cellular Oncology

JF - Molecular and Cellular Oncology

IS - 5

ER -

A scientific journey from discovery to validation of efficacy in cancer patients: HAMLET and alpha1-oleate

Abstract

Subject classification (UKÄ)

Free keywords

UN SDGs

Access to Document

Fingerprint

Cite this